Sanofi in discussions to sell a controlling stake in Opella Paris, . Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of ...

Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. We’re proud to be premium ...

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, . Sanofi advances its ambition to protect ...

Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d ...

The Sanofi of today is built on a heritage of turning the impossible into the possible for people and communities around the globe. In the last half century, Sanofi has grown into one of the world’s ...

Sanofi US (Sanofi-Aventis U.S. LLC and Sanofi US Services Inc.) respects the interest that visitors to our websites have in understanding what information is collected electronically, how it is ...

Our incredibly talented, creative scientists dig into a rich toolbox of technologies to develop smart, safe, effective medicines and vaccines that break the mold. Our integrated genomic medicine unit ...

Sanofi has strong foundations in Canada going back over a century, and operates world-leading R&D and biomanufacturing facilities in Toronto. Sanofi also operates an artificial intelligence (AI) ...

Established in Australia in 1980, with a global heritage that spans 100 years, we invest in the health of Australians by pioneering science and medicine across therapeutic areas including immunology, ...

The www.sanofi.com website (hereinafter the “site”) is owned and operated by SANOFI WINTHROP INDUSTRIE, belonging to Groupe Sanofi. The presentation and each of the elements, including trademarks, ...